Where's the value in Pfizer's $17bn Hospira buy?

With Pfizer's pending $17bn acquisition of Hospira there's a lot of interest in the target company's biosimilar portfolio, given the potential for cheaper copies of biological medicines to steal substantial market share from major drug makers, but the most valuable part of the deal for Pfizer could be the addition of Hospira's generic injectable products and manufacturing capabilities.

With Pfizer's pending $17bn acquisition of Hospira there's a lot of interest in the target company's biosimilar portfolio, given the potential for cheaper copies of biological medicines to steal substantial market share from major drug makers, but the most valuable part of the deal for Pfizer could be the addition of Hospira's generic injectable products and manufacturing capabilities.

The $90 per share transaction may contribute significant growth to Pfizer's Global Established Products (GEP) division – one of three...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Focus On Asia

  • Embracing China’s Brave New Pharmaceutical World!

     
    • By 

    Already one of the world’s largest pharmaceutical markets, China has tremendous growth potential, but significant policy and market changes are rocking the basis of competition. Multinational biopharma corporations cannot succeed in this new environment unless they fundamentally reinvent their business models to adapt to sweeping change.

  • Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

    Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

More from Scrip